Samuel Shelburne is an Infectious Disease physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 286 publications with 13,789 citations (h-index 50). By OpenAlex citation count, this profile ranks in the top 10% of Infectious Disease profiles in the FindMyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Short-acting sulfonamides32%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsPenicillins with extended spectrum24%Amoxicillin-Clavulanate Potass100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
11 NIH research awards on record, funded 2006–2026 per NIH RePORTER. The latest:
- Dynamics of Colonization and Infection by Multidrug-resistant Pathogens in Immunocompromised and Critically Ill Patients (DYNAMITE)
Methodist Hospital Research Institute
FY2025$2,377,848P01AI152999 - Project 2: Leveraging Metagenomics of the Microbiome to predict colonization/infection by antimicrobial-resistant pathogens
Methodist Hospital Research Institute
FY2025$474,264P01AI152999
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical challenges treatingStenotrophomonas maltophiliainfections: an update
JAC-Antimicrobial Resistance
2022 - Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment
Science Translational Medicine
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Thomas Walsh, MD
Cornell University
Douglas Richman, MD
University of California San Diego
Henry Masur, MD
National Institutes of Health
Vance Fowler, MD
Duke University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”